Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing

Journal of Medicinal Chemistry

Volumn 57, Issue 18, 2014, Pages 7811-7817

  Zhu, Weixing ^a   Hu, Qingzhong ^a   Hanke, Nina ^b   Van Koppen, Chris J ^b   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [(3 METHOXYPHENYL)SULFONYL] 6 (PYRIDIN 3 YLMETHYL) 1,2,3,4 TETRAHYDROQUINOLINE; 1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 6 (4,4,5,5 TETRAMETHYL 1,3,2 DIOXABOROLAN 2 YL) 1,2,3,4 TETRAHYDROQUINOLINE; 6 (PYRIDIN 3 YLMETHYL) 1,2,3,4 TETRAHYDROQUINOLINE; AROMATASE; CYTOCHROME P450 17; OXYGENASE INHIBITOR; STEROID 11BETA MONOOXYGENASE; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT; ALDOSTERONE SYNTHASE; AROMATASE INHIBITOR; CYTOCHROME P450 INHIBITOR;

ARTICLE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IC50; LIVER; MUTAGENICITY; PLASMA; WOUND FLUID; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; METABOLISM; WOUND HEALING;

AROMATASE; AROMATASE INHIBITORS; CYTOCHROME P-450 CYP11B2; CYTOCHROME P-450 ENZYME INHIBITORS; DRUG DESIGN; DRUG STABILITY; HUMANS; LIVER; STEROID 11-BETA-HYDROXYLASE; WOUND HEALING;

EID: 84907462346     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501004t     Document Type: Article

References (44)

1. Sen, C. K.; Gordillo, G. M.; Roy, S.; Kirsner, R.; Lambert, L.; Hunt, T. K.; Gottrup, F.; Gurtner, G. C.; Longaker, M. T. Human skin wounds: a major and snowballing threat to public health and the economy Wound Repair Regener. 2009, 17, 763-771
2. Guo, S.; DiPietro, L. A. Factors affecting wound healing J. Dent. Res. 2010, 89, 219-229
3. Brem, H.; Tomic-Canic, M. Cellular and molecular basis of wound healing in diabetes J. Clin. Invest. 2007, 117, 1219-1222
4. Chronic wound care guidelines. http://woundheal.org/documents/final-pocket-guide-treatment.aspx (accessed Jun 12, 2014).
5. Montfrans, C. V.; Stok, M.; Geerkens, M. Biology of chronic wounds and new treatment strategies Phlebology 2014, 19, 165-167
6. Gosain, A.; DiPietro, L. A. Aging and wound healing World J. Surg. 2004, 28, 321-326
7. Ebrecht, M.; Hextall, J.; Kirtley, L.; Taylor, A.; Dyson, M.; Weinman, J. Perceived stress and cortisol levels predict speed of wound healing in healthy male adults Psychoneuroendocrinology 2004, 29, 798-809
8. Vukelic, S.; Stojadinovic, O.; Pastar, I.; Rabach, M.; Krzyzanowska, A.; Lebrun, E.; Davis, S. C.; Resnik, S.; Brem, H.; Tomic-Canic, M. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury J. Biol. Chem. 2011, 286, 10265-10275
9. Shah, M. G.; Maibach, H. I. Estrogen and skin. An overview Am. J. Clin. Dermatol. 2001, 2, 143-150
10. Slominski, A.; Zbytek, B.; Nikolakis, G.; Manna, P. R.; Skobowiat, C.; Zmijewski, M.; Li, W.; Janjetovic, Z.; Postlethwaite, A.; Zouboulis, C. C.; Tuckey, R. C. Steroidogenesis in the skin: implications for local immune functions J. Steroid. Biochem. Mol. Biol. 2013, 137, 107-123
11. Trengove, N. J.; Langton, S. R.; Stacey, M. C. Biochemical analysis of wound fluid from nonhealing and healing chronic leg ulcers Wound Repair Regener. 1996, 4, 234-239
12. Derendorf, H.; Nave, R.; Drollmann, A.; Cerasoli, F.; Wurst, W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Eur. Respir. J. 2006, 28, 1042-1050
13. Yin, L.; Lucas, S.; Maurer, F.; Kazmaier, U.; Hu, Q.; Hartmann, R. W. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1- ij ]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome J. Med. Chem. 2012, 55, 6629-6633
14. Emmerich, J.; Hu, Q.; Hanke, N.; Hartmann, R. W. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type J. Med. Chem. 2013, 56, 6022-32
15. Yin, L.; Hu, Q.; Emmerich, J.; Lo, M. M.; Metzger, E.; Ali, A.; Hartmann, R. W. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors J. Med. Chem. 2014, 57, 5179-5189
16. Ehmer, P. B.; Bureik, M.; Bernhardt, R.; Muller, U.; Hartmann, R. W. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells J. Steroid Biochem. Mol. Biol. 2002, 81, 173-179
17. Hu, Q.; Yin, L.; Jagusch, C.; Hille, U. E.; Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors J. Med. Chem. 2010, 53, 5049-5053
18. Hille, U. E.; Hu, Q.; Vock, C.; Negri, M.; Bartels, M.; Mueller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modeling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls Eur. J. Med. Chem. 2009, 44, 2765-2775
19. Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Hu, Q.; Hille, U. E.; Jagusch, C.; Jahn-Hoffmann, K.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Hartmann, R. W. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modeling Arch. Pharm. (Weinheim, Ger.) 2008, 341, 597-609
20. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part II: Core rigidification and influence of substituents at the methylene bridge Bioorg. Med. Chem. 2008, 16, 7715-7727
21. Hu, Q.; Jagusch, C.; Hille, U. E.; Haupenthal, J.; Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenyl methylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer J. Med. Chem. 2010, 53, 5749-5758
22. Yin, L.; Hu, Q. CYP17 inhibitors-abiraterone, C17,20-lyase inhibitors and multi-targeting agents Nat. Rev. Urol. 2014, 11, 32-42
23. Krug, S. J.; Hu, Q.; Hartmann, R. W. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition J. Steroid Biochem. Mol. Biol. 2013, 134, 75-79
24. Hu, Q.; Negri, M.; Olgen, S.; Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma ChemMedChem 2010, 5, 899-910
25. Hille, U. E.; Hu, Q.; Pinto-Bazurco Mendieta, M. A. E.; Bartels, M.; Vock, C. A.; Lauterbach, T.; Hartmann, R. W. Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile C. R. Chim. 2009, 12, 1117-1126
26. Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation and molecular modeling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: Heterocyclic modifications of the core structure Bioorg. Med. Chem. 2008, 16, 1992-2010
27. Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Jagusch, C.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer J. Med. Chem. 2008, 51, 5009-5018
28. Yin, L.; Hu, Q.; Hartmann, R. W. Recent progress in pharmaceutical therapy for castration-resistant prostate cancer Int. J. Mol. Sci. 2013, 14, 13958-13978
29. Lézé, M.-P.; Le Borgne, M.; Pinson, P.; Palusczak, A.; Duflos, M.; Le Bauta, G.; Hartmann, R. W. Synthesis and biological evaluation of 5-[(aryl)(1 H -imidazol-1-yl)methyl]-1 H -indoles: potent and selective aromatase inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 1134-1137
30. Gobbi, S.; Cavalli, A.; Negri, M.; Schewe, K. E.; Belluti, F.; Piazzi, L.; Hartmann, R. W.; Recanatini, M.; Bisi, A. Imidazolylmethylbenzophenones as highly potent aromatase inhibitors J. Med. Chem. 2007, 50, 3420-3422
31. Hartmann, R. W.; Frotscher, M.; Ledergerber, D.; Wächter, G. A.; Grün, G. L.; Sergejew, T. F. Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2 Arch. Pharm. (Weinheim, Ger.) 1996, 329, 251-261
32. Gobbi, S.; Hu, Q.; Negri, M.; Zimmer, C.; Belluti, F.; Rampa, A.; Hartmann, R. W.; Bisi, A. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 11betahydroxylase inhibition J. Med. Chem. 2013, 56, 1723-1729
33. Abadi, A. H.; Abou-Seri, S. M.; Hu, Q.; Negri, M.; Hartmann, R. W. Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors MedChemComm 2012, 3, 663-666
34. Hu, Q.; Yin, L.; Hartmann, R. W. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases J. Med. Chem. 2014, 57, 5011-5022
35. Hu, Q.; Yin, L.; Hartmann, R. W. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer J. Med. Chem. 2012, 55, 7080-7089
36. Yin, L.; Hu, Q.; Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks J. Med. Chem. 2013, 56, 460-470
37. Yin, L.; Hu, Q. Drug discovery for breast cancer and coinstantaneous cardiovascular disease: What is the future? Future Med. Chem. 2013, 5, 359-362
38. Pinto-Bazurco Mendieta, M. A. E.; Hu, Q.; Engel, M.; Hartmann, R. W. Highly potent and selective non-steroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases J. Med. Chem. 2013, 56, 6101-6107
39. Roumen, L.; Peeters, J. W.; Emmen, J. M. A.; Beugels, I. P. E.; Custers, E. M. G.; de Gooyer, M.; Plate, R.; Pieterse, K.; Hilbers, P. A. J.; Smits, J. F. M.; Vekemans, J. A. J.; Leysen, D.; Ottenheijm, H. C. J.; Janssen, H. M.; Hermans, J. J. R. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1 H -imidazoles as selective inhibitors of aldosterone synthase (CYP11B2) J. Med. Chem. 2010, 53, 1712-1725
40. Yin, L.; Hu, Q.; Hartmann, R. W. 3-Pyridinyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2 PLoS One 2012, 7 (11) e48048
41. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1 H -quinolin-2-one derivatives J. Med. Chem. 2008, 51, 8077-8087
42. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach J. Med. Chem. 2008, 51, 6138-6149
43. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Müller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity J. Med. Chem. 2008, 51, 5064-5074
44. Voets, M.; Antes, I.; Scherer, C.; Müller-Vieira, U.; Biemel, K.; Marchais-Oberwinkler, S.; Hartmann, R. W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis J. Med. Chem. 2006, 49, 2222-2231